✦ LIBER ✦

Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia

✍ Scribed by Halla S. Nimeiri; Amit M. Oza; Robert J. Morgan; Gregory Friberg; Kristen Kasza; Leonardo Faoro; Ravi Salgia; Walter M. Stadler; Everett E. Vokes; Gini F. Fleming

Book ID: 113961542
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 256 KB
Volume: 110
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2008.02.009

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II clinical trial of pegylated l

A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer

✍ Marcela G. del Carmen; John Micha; Laurie Small; Daron G. Street; Anil Londhe; T 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 254 KB

Phase II study of bevacizumab and pemetr

Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer

✍ Hagemann, Andrea R.; Novetsky, Akiva P.; Zighelboim, Israel; Gao, Feng; Massad, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 264 KB

Phase II evaluation of topotecan and nav

Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer

✍ Thomas J. Herzog; Matthew A. Powell; Janet S. Rader; Randall K. Gibb; Lynne Lipp 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 424 KB

STAC: A phase II study of carboplatin/pa

STAC: A phase II study of carboplatin/paclitaxel/bevacizumab followed by randomization to either bevacizumab alone or erlotinib and bevacizumab in the upfront management of patients with ovarian, fallopian tube or peritoneal cancer

✍ S. Campos; T. Atkinson; S. Berlin; M. Roche; C. Whalen; U. Matulonis; N. Horowit 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 48 KB

A phase II study of GM-CSF and rIFN-γ1b

A phase II study of GM-CSF and rIFN-γ1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer

✍ Kathleen M. Schmeler; Saroj Vadhan-Raj; Pedro T. Ramirez; Sachin M. Apte; Lorenz 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 402 KB

Treatment of recurrent or persistent pla

Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: A phase II trial of the Puget Sound Oncology Consortium

✍ Barbara A. Goff; Leona A. Holmberg; Dan Veljovich; Brenda F. Kurland 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 288 KB